Diabetes drug could improve heart failure treatment

NCT ID NCT04438213

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial at Yale University is testing whether the diabetes drug ertugliflozin can help people with chronic heart failure manage fluid buildup better than a standard diuretic (metolazone) or a placebo. Sixty adults on daily diuretics will take one of the three treatments for six weeks. Researchers will measure changes in blood volume and sodium excretion to see if ertugliflozin offers unique benefits without causing dehydration.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ertugliflozin (a diabetes drug) and metolazone (a diuretic)
What this could lead to: If successful, this could show that ertugliflozin helps manage heart failure better than standard diuretics, with fewer side effects like dehydration.
What could go wrong: This is a small, early-phase study (60 people) looking at short-term effects. It may not prove long-term benefit or safety, and results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Yale School of Medicine
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.